Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

@article{Baum2002AnastrozoleAO,
  title={Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.},
  author={Michael Baum and A U Budzar and Jack Cuzick and John F. Forbes and Jennifer Houghton and Jan G. M. Klijn and Tarek Sahmoud},
  journal={Lancet},
  year={2002},
  volume={359 9324},
  pages={2131-9}
}
BACKGROUND In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, it is associated with several side-effects including endometrial cancer and thromboembolic disorders. We aimed to compare the safety and efficacy outcomes of tamoxifen with those of anastrozole alone and the combination of anastrozole plus tamoxifen for 5 years. METHODS Participants were postmenopausal patients with invasive operable breast cancer… CONTINUE READING
Highly Influential
This paper has highly influenced 26 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
544 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 544 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

The effect of anastrozole ( ‘ Arimidex ’ ) on serum lipids : a randomized comparison of anastrozole ( AN ) vs . tamoxifen ( TAM ) in postmenopausal women with advanced breast cancer

  • J Dewar, JM Nabholtz, J Bonneterre, AU Buzdar
  • Semin Oncol
  • 2001

Similar Papers

Loading similar papers…